Sarit Assouline - Concepedia

Author

Sarit Assouline

McGill University

Also Known As

S Assouline, S. Assouline, S. E. Assouline, Sarit Assouline, Sarit E Assouline, Sarit E. Assouline

110

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

McGill University Jewish General Hospital Princess Margaret Cancer Centre Simon Fraser University McGill University Health Centre

About

Sarit Assouline is an author at McGill University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.3K
2	Engineering	2	2	48
3	Cell Biology	2	2	191
4	Health Sciences	1	1	56
5	Immunology	1	1	109

Sarit Assouline

Publications

Citations

H-Index

Page 1

	Year	Citations
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, The Lancet Oncology Lymphoid NeoplasiaOncologyMalignant Blood DisorderRefractory Follicular LymphomaDermatology	2020	556
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy L. John Hoffer, Mark Levine, Sarit Assouline, Annals of Oncology Ascorbic AcidHematological MalignancyOncologyAdvanced MalignancyMedicine	2008	369
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas Ryan D. Morin, Sarit Assouline, Miguel Alcaide, Clinical Cancer Research	2015	221
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation Hiba Ahmad Zahreddine, Biljana Culjkovic‐Kraljacic, Sarit Assouline, Nature MedicineGlycobiologyPharmacologyCell BiologyDrug Discovery	2014	180
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma Sarit Assouline, Torsten Holm Nielsen, Stephen Yu, Blood	2016	139
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma Christopher Rushton, Sarah E. Arthur, Miguel Alcaide, Blood Advances ImmunologyPathologyImmunotherapyTreatment ResistanceTumor Biology	2020	109
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma Connie Lee Batlevi, Michael Crump, Charalambos Andreadis, British Journal of Haematology	2017	105
Hormone replacement therapy use and variations in the risk of breast cancer Lucie Opatrny, Sophie Dell’Aniello, Sarit Assouline, BJOG An International Journal of Obstetrics & Gynaecology	2007	90
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172) C. Tom Kouroukis, Louis A. V. Fernandez, Michael Crump, Leukemia & lymphoma/Leukemia and lymphoma Hematological MalignancyNational Cancer InstituteTranslational MedicineGemcitabine 1000Lymphoid Neoplasia	2011	56
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma Miguel Alcaide, Stephen Yu, Kevin Bushell, Clinical Chemistry	2016	51

Page 1